Nautilus Biotechnology
Nautilus Biotechnology is a development-stage life sciences company building a single-molecule proteome analysis platform called Voyager™...
Facts
- HQ
- Seattle
- Sectors
- Biotechnology Research
- Founded
- 2016
- Employees
- 150
- Stage
- Public
- Total raised
- $200M SEC Form D filings Total of this company's SEC Form D filings
- Last round
- $200M · Jun 2021 SEC Form D
- Founders
- Sujal Patel, Parag Mallick, PhD
Athira Pharma raises $85M Series B to push NDX-1017 toward FDA approval for Alzheimer’s, Parkinson’s and ALS
Seattle biotech Athira Pharma raised $85 million in a Series B round to advance NDX-1017, a regenerative therapy aimed at halting or reversing nerve damage in Alzheimer’s, Parkinson’s and ALS, with preliminary trial results reported as positive and potential market availability in 2–3 years.
Nautilus Biotechnology raises $76M Series B led by Vulcan Capital; Bezos Expeditions among investors, total funding tops $100M
Nautilus Biotechnology, co-founded by Stanford scientist Parag Mallick and Isilon co-founder Sujal Patel, revealed a platform to study the human proteome and announced a $76 million Series B led by Vulcan Capital with participation from Bezos Expeditions, Perceptive Advisors and others. The round brings total funding above $100 million for the 50-person startup as it exits stealth to accelerate proteomics-driven therapeutics development.
People
-
Sujal Patel Executive, Co-founder and CEO, Executive Officer, Director
